NRAS and melanoma: Additionally, the mutation status of BRAF, NRAS and CKIT (key proto‐oncogenes in melanoma; from the targeted sequencing analysis originally reported in ref. 22) was consistent across metastases within the same patient in 22 out of the 24 cases, indicating minimal proto‐oncogene heterogeneity (Figure 1A and Table S1).